The AMR Accelerator is an IMI Programme that comprises 7 projects with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections.
The AMR Accelerator aims to deliver up to 10 new preclinical candidates and 5 Phase II-ready assets by 2025.
Learn more about the Accelerator Projects
Follow us:
| The AMR Accelerator has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreements No 853967 I 853989 I 853979 I 853932 I 853800 I 853903 I 853976 I 101007873 I 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. ERA4TB receives additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. UNITE4TB receives additional support from Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. https://www.imi.europa.eu/ |